MedTrace Logo

MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

NCT04073966 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-09-19

No results posted yet for this study

Summary

Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. The overarching goal of this study is to better understand the determinants of RT-associated changes in white and gray matter function and associated neurocognitive decline.

Conditions

  • Brain Metastases
  • Neurocognitive Deficit
  • White Matter Alterations
  • Radiation Exposure

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Colette J Shen, MD, PhD · University of North Carolina at Chapel Hill, Department of Radiation Oncology

  • Tong Zhu, PhD, DABR · University of North Carolina at Chapel Hill, Department of Radiation Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2026-09-15
Completion
2026-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04073966 on ClinicalTrials.gov